Dyslipidemia in Chronic Kidney Disease: Managing a High-Risk Combination

References

• . National Kidney Foundation. KDOQI Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease. Am J Kidney Dis. 2003;41( suppl 3):S1–S92
   PubMed Web of Science ®Google Scholar
• . Levey AS, Beto JA, Coronado BE, . Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis. 1998;32(5):853–906
   PubMed Web of Science ®Google Scholar
• . Fox CH, Voleti V, Khan LS, Murray B, Vassalotti J. A quick guide to evidence based chronic kidney disease care for the primary care physician. Postgrad Med. 2008;120(2):E01–E06
   Google Scholar
• . Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–2497
   PubMed Web of Science ®Google Scholar
• . Sekkarie M, Cosma M, Mendelssohn D. Nonreferral and nonacceptance to dialysis by primary care physicians and nephrologists in Canada and the United States. Am J Kidney Dis. 2001;38(1):36–41
   Google Scholar
• . Keane WF, Kasiske BL, O'Donnell MP. Lipids and progressive glomerulosclerosis. A model analogous to atherosclerosis. Am J Nephrol. 1988;8(4):261–271
   PubMed Web of Science ®Google Scholar
• . Mühlfeld AS, Spencer MW, Hudkins KL, Kirk E, LeBoeuf RC, Alpers CE. Hyperlipidemia aggravates renal disease in B6.ROP Os/+ mice. Kidney Int. 2004;66(4):1393–1402
   Google Scholar
• . Samuelsson O, Mulec H, Knight-Gibson C, . Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant. 1997;12(9):1908–1915
   PubMed Web of Science ®Google Scholar
• . Rahman M, Baimbridge C, Davis BR, ; ALLHAT Collaborative Research Group. Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Am J Kidney Dis. 2008;52(3):412–424
   PubMed Web of Science ®Google Scholar
• . Shepherd J, Kastelein JJ, Bittner V, ; Treating to New Targets Investigators. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol. 2007;2(6):1131–1139
   PubMedGoogle Scholar
• . Fellström B, Holdaas H, Jardine AG, ; AURORA Study Group. Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study. Kidney Blood Press Res. 2007;30(5):314–322
   Google Scholar
• . Wanner C, Krane V, März W, ; German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238–248
   PubMed Web of Science ®Google Scholar
• . Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl. 2003;(84):S207–S10
   Google Scholar
• . Weiner DE, Sarnak MJ. Managing dyslipidemia in chronic kidney disease. J Gen Intern Med. 2004;19(10):1045–1052
   Google Scholar
• . Kasiske BL. Hyperlipidemia in patients with chronic renal disease. Am J Kidney Disease. 1998;32(5 suppl 3):S142–S156
   PubMed Web of Science ®Google Scholar
• . Attman PO, Samuelsson O, Johansson AC, Moberly JB, Alaupovic P. Dialysis modalities and dyslipidemia. Kidney Int Suppl. 2003;(84):S110–S112
   Google Scholar
• . Attman PO, Knight-Gibson C, Tavella M, Samuelsson O, Alaupovic P. The compositional abnormalities of lipoproteins in diabetic renal failure. Neprol Dial Transplant. 1998;13(11):2833–2841
   Google Scholar
• . Liu Y, Coresh J, Eustace J, . Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA. 2004;291(4):451–459
   PubMed Web of Science ®Google Scholar
• . Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Inverse association between lipid levels and mortality in men with chronic kidney disease who are not yet on dialysis: effects of case mix and the malnutrition-inflammation-cachexia syndrome. J Am Soc Nephrol. 2007;18(1):304–311
   Google Scholar
• . Volpato S, Zuliani G, Guralnik JM, Palmieri E, Fellin R. The inverse association between age and cholesterol levels among older patients: the role of poor health status. Gerontology. 2001;47(1):36–45
   PubMed Web of Science ®Google Scholar
• . Grundy SM, Cleeman JI, Merz CN; Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004;44(3):720–732
   PubMedGoogle Scholar
• . Holdaas H, Fellström B, Jardine AG, ; Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003;361(9374):2024–2031
   PubMed Web of Science ®Google Scholar
• . Baigent C, Landray M, Leaper C, ; First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis. 2005;45(3):473–484
   PubMed Web of Science ®Google Scholar
• . Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C; American College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Stroke. 2002;33(9):2337–2341
   PubMed Web of Science ®Google Scholar
• . Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol. 1998;81(4A):7B–12B
   PubMed Web of Science ®Google Scholar
• . Assmann G, Schulte H, Funke H, von Eckardstein A. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J. 1998;19( suppl M):M8–M14
   Google Scholar
• . Cui Y, Blumenthal RS, Flaws JA, . Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med. 2001;161(11):1413–1419
   PubMedGoogle Scholar
• . Abate N, Vega GL, Grundy SM. Variability in cholesterol content and physical properties of lipoproteins containing apolipoprotein B-100. Atherosclerosis. 1993;104(1–2):159–171
   Google Scholar
• . Seres DS, Strain GW, Hashim SA, Goldberg IJ, Levin NW. Improvement of plasma lipoprotein profiles during high-flux dialysis. J Am Soc Nephrol. 1993;3(7):1409–1415
   Google Scholar
• . Levy RI, Troendle AJ, Fattu JM. A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin. Circulation. 1993;87( 4 suppl):III45–III53
   PubMed Web of Science ®Google Scholar
• . Harris KP, Wheeler DC, Chong CC; Atorvastatin in CAPD Study Investigators. A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD. Kidney Int. 2002;61(4):1469–1474
   Google Scholar
• . Chang JW, Yang WS, Min WK, Lee SK, Park JS, Kim SB. Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis. 2002;39(6):1213–1217
   Google Scholar
• . Tonelli M, Moyé L, Sacks FM; Cholesterol and Recurrent Events (CARE) Trial Investigators. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med. 2003;138(2):98–104
   PubMedGoogle Scholar
• . Atthobari J, Brantsma AH, Gansevoort RT, ; PREVEND study group. The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study. Nephrol Dial Transplant. 2006;21(11):3106–3114
   PubMed Web of Science ®Google Scholar
• . Gotto AM Jr, Farmer JA. Pleitropic effects of statins: do they matter? Curr Opin Lipidol. 2001;12(4):391–394
   Google Scholar
• . Munford RS. Statins and the acute-phase response. N Engl J Med. 2001;344(26):2016–2018
   Google Scholar
• . Stenvinkel P, Heimbürger O, Paultre F, . Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999;55(5):1899–1911
   PubMed Web of Science ®Google Scholar
• . Kasiske B, Cosio FG, Beto J, ; National Kidney Foundation. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant. 2004;4( suppl 7):13–53
   PubMed Web of Science ®Google Scholar